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Melanoma is rapidly increasing in incidence throughout the world. Early stages are curable with 
surgical approaches with excellent prognosis. However, a substantial proportion of patients 
progress to metastatic disease with survival rates of less than 5% making melanoma the culprit 
for over 65% of all skin-cancer related deaths. Novel agents targeting the immune system and the 
signaling pathways of melanoma are generating new promise, but chemotherapy remains an 
important therapeutic alternative, despite low response rates. The resistance of melanoma to 
chemotherapy is in part due to DNA repair mechanisms that allow cells to survive alkylation 
damage. Several novel agents targeting the abrogation of DNA repair pathways alone and in 
combination with cytotoxic agents have been developed with varying measures of success. In 
this dissertation, we first identified the epigenetic silencing of the DNA mismatch repair (MMR) 
gene MLH1 as a determinant of response and survival for melanoma patients treated with 
alkylator-based chemotherapy (dacarbazine/ temozolomide). We then determined the safe dosage 
of the epigenetic agent decitabine that can be administered in combination with temozolomide. 
The safety, tolerability and efficacy of the combination of decitabine and temozolomide were 
evaluated in a Phase II population. We finally determined the pharmacokinetic and 
pharmacodynamic effects of treatment with the combination of decitabine and temozolomide in 
the blood and tumor tissues of metastatic melanoma patients. 
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1.0  INTRODUCTION 
1.1 IMPACT OF MELANOMA 
Skin cancer has become the most common neoplasm in the United States, with incidence 
reaching epidemic proportions. The American Cancer Society estimates that more than 2 million 
new cases of basal cell or squamous cell carcinoma, and more than 68,000 new cases of 
malignant melanoma are diagnosed annually 1. An estimated 1 in 5 Americans will develop skin 
cancer in their lifetime 2. Overall, the lifetime risk of getting melanoma is about 2% (1 in 50) for 
whites, 0.1% (1 in 1,000) for blacks, and 0.5% (1 in 200) for Hispanics 3. With early diagnosis 
and appropriate management, most skin cancers have an overall 5-year survival rate of 95%. 
However, melanoma has a significantly higher morbidity and mortality. Although it is the third 
most common skin cancer, accounting for only 3% of all skin cancers, melanoma accounts for 
65% of all skin cancer deaths 4. 
Melanoma is the fifth most common cancer in men and the sixth in women in the United 
States. From 1981 to 2002 the incidence of cutaneous melanoma has increased nearly 2.8-fold. 
This increase is associated with an increased tendency to perform biopsies on pigmented lesions 
and has resulted in increased diagnosis of thin (<1 mm) melanoma 5. It is not entirely clear why 
we have failed to see a decrease in mortality with earlier detection 6. The annual incidence of 
melanoma in the United States between 1998 and 2002 was 17.2 per 100,000 population, a sharp 
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increase from 5.7 per 100,000 population reported in 1973 7. The annual cost of treating newly 
diagnosed melanoma was estimated to exceed $550 million in 1997 8. A more recent analysis 
estimate the annual cost to be more than $250 million for patients over the age of 65 years alone 
9. 
1.2 ROLE OF CHEMOTHERAPY IN METASTATIC MELANOMA 
Early stages of melanoma are surgically curable and adjuvant therapy of high-risk disease is 
modestly effective in preventing recurrent metastatic disease 10. Once metastatic, melanoma is 
incurable with very high disease-fatality rates. The survival rate at 5 years for patients with 
metastatic disease is <10% with a median survival of 6-9 months 11. Hydroxyurea was the first 
agent to get FDA approval in 1967 followed by dacarbazine in 1971, which quickly became the 
“standard of care” as no other agent, singly or in combination, achieved a survival advantage 
over single-agent dacarbazine 12. 
In this setting, dacarbazine was the only standard option for many patients but for the 
oncology community in actuality, the standard of care was enrollment on clinical trials. Among 
the 8 randomized trials in which dacarbazine was used as a comparator arm since 1992, more 
than 1,000 patients have been treated with dacarbazine with an overall response rate of 13.4% 13. 
The oral agent temozolomide (TMZ) is rapidly converted to the same methylating active moiety 
as dacarbazine (MTIC) and is widely used for the treatment of metastatic melanoma. TMZ has 
an improved pharmacokinetic and safety profile and good CNS penetration, making it a welcome 
addition to the armamentarium of the melanoma oncologist and investigative community 14. 
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Randomized trials have confirmed that TMZ is at least equivalent to dacarbazine but due to its 
oral mode of administration, this therapy improves modestly on quality of life 15.  
Very few agents have shown clinical benefit in the metastatic melanoma setting and none 
has shown a survival advantage for over 3 decades prior to 2011. Immunotherapy has achieved 
limited success with high-dose bolus IL-2 leading to durable responses in a small subset of 
patients (5-15%) 16. Recent hope was sparked with the benefit observed with the anti-CTLA4 
antibody, ipilimumab, in the first-ever metastatic melanoma trial to show improvement of overall 
survival leading to FDA approval in March 2011 17. The approval of ipilimumab will alter the 
therapeutic landscape of metastatic melanoma and offer effective options for patients with this 
devastating disease. However, the enthusiasm is tempered by the fact that only 10-15% of 
patients respond and not all achieve durable responses. Patients that do not respond to 
ipilimumab or progress on it will still need to be treated with alternative approaches including 
chemotherapy.  
Equally promising has been the advent of highly selective BRAF-targeted agents that 
have lead to the highest response rates seen in melanoma, in patients that harbor the BRAF 
mutation 18. This is highly encouraging although, to date, no durable responses have been 
described with BRAF inhibitors. Also, those agents are only available for the 40-50% of patients 
whose tumors demonstrated the mutation. Consequently, patients that a) are wild-type for BRAF; 
b) have the BRAF mutation but do not respond to BRAF inhibitors; or c) progress on BRAF 
inhibition, will demand that we have improved options in cytotoxic chemotherapy.  
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1.3 CHEMOTHERAPY RESISTANCE IN METASTATIC MELANOMA 
Melanoma resistance to chemotherapy is a major impediment to improving outcomes in patients 
with this disease. The mechanisms underlying such resistance appear to be closely tied to 
dysregulation of DNA repair pathways in cancer cells. DNA repair pathways (Figure 1) are 
present in normal cells to maintain genome integrity. Multiple pathways are activated in response 
to the genotoxic damage induced by chemotherapy, starting with recognition of DNA damage 
and culminating in programmed cell death 19. Failure at any point along this cascade of events 
can be translated into resistance. A deeper understanding of the DNA repair pathways, 
implicated as primary mechanisms of resistance, has guided the development of several 
strategies targeting DNA repair to overcome chemotherapy resistance in melanoma.  While 
inhibition of the direct reversal mechanism, O6-methylguanine DNA-methyltransferase (MGMT) 
was not met with much success, dual inhibition approaches targeted at MGMT and DNA 
mismatch repair (MMR) concomitantly may allow the exploitation of its therapeutic potential 20, 
21. The promising results observed in early clinical trials of PARP inhibitors may give this field 
additional momentum and provide chemotherapy resistance abrogation new and exciting 
horizons 22, 23.  
The successful development of DNA repair inhibitors is still incumbent upon the 
development of appropriate biomarkers and innovative clinical trial design. Coupling biomarker 
development with rational combination strategies in carefully designed translational clinical 
trials offers great hope for improving therapy outcomes in patients with metastatic melanoma. 
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1.4 ROLE OF EPIGENETICS IN CHEMOTHERAPY RESISTANCE ABROGATION  
Epigenetics is defined as heritable changes in gene expression without a change in the DNA 
sequence itself 24. DNA methylation is an important epigenetic mechanism that has profound 
roles in gene regulation, development, and carcinogenesis 25, 26. DNA methylation and histone 
modifications are involved in the reprogramming of the genome of mammalian cells in cancer 27. 
In melanoma at least 50 genes have been identified to date to become silenced by promoter 
hypermethylation during development and progression of disease 28. DNA methylation consists 
of the addition of a methyl group by DNA methyltransferases (DNMTs) to the 5 position of a 
cytosine ring located in CpG islands 29. DAC, a potent DNMT inhibitor licensed for 
myelodysplastic syndromes, reverses promoter methylation and leads to re-expression of 
epigenetically silenced genes (e.g. MMR proteins MLH1, MSH2, MSH6) with the potential to 
reverse the chemotherapy-resistant phenotype 30-32.  
It can be hypothesized that epigenetically controlled genes can constitute part of an 
epigenetic marker associated with the chemotherapy-resistant phenotype. It could therefore be 
expected that agents targeting DNA methylation and histone deacetylation would reverse the 
resistance phenotype by modulating the epigenetic marker. 
1.5 STATEMENT OF PROBLEM 
A deeper understanding of epigenetic mechanisms underlying chemotherapy resistance in 
metastatic melanoma provides the opportunity to describe the observed chemotherapy-resistant 
phenotype as well as to modulate it pharmacologically.  
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In this dissertation, we will examine: 1) the role of epigenetic silencing of the DNA 
mismatch repair gene MLH1 in melanoma response to chemotherapy; 2) the safety, tolerability, 
and efficacy of the addition of the epigenetic agent decitabine to the chemotherapeutic agent 
temozolomide in metastatic melanoma; 3) the pharmacokinetic and pharmacodynamic effects of 
the addition of decitabine to temozolomide in patients with metastatic melanoma.  
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2.0  EPIGENETIC SILENCING OF THE DNA MISMATCH REPAIR GENE MLH1 IS 
ASSOCIATED WITH SURVIVAL AND RESPONSE TO ALKYLATOR-BASED 
CHEMOTHERAPY IN METASTATIC MELANOMA  
2.1 INTRODUCTION 
The monofunctional alkylating agents, dacarbazine and temozolomide (TMZ), remain the 
mainstay of chemotherapy for metastatic melanoma, with response rates of less than 10% 33. In a 
recent pooled data analysis of 42 NCI-funded Phase II clinical trials of melanoma, the only 
parameters correlated with favorable outcomes in metastatic melanoma were clinical 
characteristics such as performance status, presence or absence of visceral or brain metastases 34. 
Those factors are widely considered important for prognostication but do not serve to predict 
response to therapy.  
Both TMZ and dacarbazine (DTIC) are converted after administration to the cytotoxic 
entity 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) 35, 36. MTIC directly methylates 
DNA resulting in methyl-DNA lesions at specific sites (Figure 1). The O6- methylguanine (O6-
meG) is considered to be responsible for most of alkylator cytotoxicity 19, 37. DNA repair 
mechanisms can reverse DNA damage and result in cell survival and therefore tumor resistance. 
O6-meG can be repaired by O6-methylguanine methyltransferase (MGMT) in a process termed 
direct reversal 38. O6-meG lesions that are not repaired by MGMT mismatch with thymine and 
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become a substrate of the DNA mismatch repair system (MMR). A functional MMR is necessary 
to activate mechanisms culminating in cell death 39-42. Thus, the efficacy of TMZ or dacarbazine 
therapy may strongly depend on low MGMT together with high MMR expression 43. 
Epigenetic inactivation of genes crucial for control of normal cell growth is a hallmark of 
cancer cells 44.The transfer of a methyl group to the carbon 5 position of cytosines, almost 
always in the context of CpG dinucleotides, is the only known epigenetic modification of DNA 
itself in mammalian cells. Many tumors show increased methylation of CpG islands, CpG rich 
regions of DNA usually although not exclusively associated with gene promoters, which is 
associated with epigenetic silencing 45. CpG islands aberrantly methylated in tumors are 
associated with silencing of genes involved in control of the cell cycle, apoptosis and drug 
sensitivity as well as tumor suppressor genes 46, 47. The epigenetic modulation of genes has been 
shown to play a significant role in chemotherapy resistance as demonstrated by the marked 
hypermethylation and silencing of numerous components of DNA repair mechanisms within 
cancer cells, such as MGMT, MLH1, BRCA1, and WRN, in addition to the hypermethylation and 
silencing of genes associated with apoptosis, such as RASSF1A, DAPK, TMS1, APAF-1, and 
IGFBP36 48. 
Low MGMT levels have been associated with improved response to TMZ-based therapy 
49. This has been shown to occur through hypermethylation and epigenetic silencing of the CpG 
island of MGMT resulting in improved response of glioma to temozolomide 50. The MLH1 
protein, part of the MMR system, is important in determining sensitivity to a number of 
important chemotherapeutic agents including alkylating agents and cisplatin 51, 52. We 
investigated the role of epigenetic regulation on the expression of DNA repair genes in general, 
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and MLH1 in particular, in correlation with alkylator-based chemotherapy outcomes in patients 
with metastatic melanoma.  
2.2 PATIENTS AND METHODS 
2.2.1 Study Design 
Using a retrospective cohort study design, we evaluated 66 patients with metastatic 
melanoma who were treated with alkylator-based chemotherapy at the Melanoma Center of the 
University of Pittsburgh Cancer Institute between 2000 and 2007. Patients were identified 
through the institution's medical record data repository. This repository contains whole-text 
medical records and integrates information from central transcription, laboratory, pharmacy, 
finance, administrative, and other departmental databases throughout the University of Pittsburgh 
Medical Center 53. To meet HIPAA guidelines and ensure patient confidentiality, all data was de-
identified (De-ID Software, University of Pittsburgh) using an honest broker system. This study 
met the criteria for exemption of informed consent by the University of Pittsburgh Institutional 
Review Board (UPCI 08-009). Tumor samples were obtained from the Health Sciences Tissue 
Bank (HSTB) at the University of Pittsburgh Cancer Institute. Formalin-fixed paraffin-embedded 
(FFPE) tissues were available from metastatic lesions on all patients and only patients with 
available pre-treatment tumor specimens were included in this analysis (n=66). 
Chemotherapy regimens studied were primarily single-agent dacarbazine, single-agent 
temozolomide (TMZ) or dacarbazine-based combinations (including CVD, Cisplatin + 
Vinblastine + dacarbazine). Patients could have received immunotherapy (interferon or 
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interleukin-2) in the adjuvant or metastatic setting. Any other form of chemotherapy was 
excluded from this analysis. Response to chemotherapy was defined as documented objective 
tumor regression upon treatment with chemotherapy. Patients were considered responders if their 
objective response by RECIST criteria was partial response or complete response after 2 or more 
cycles of chemotherapy. Patients with stable disease or disease progression after 2 cycles of 
chemotherapy were considered non-responders.  
2.2.2 Illumina Infinium Methylation Analysis 
DNA was isolated from melanoma FFPE tissues using the RecoverAllTM Total Nucleic Acid 
Isolation kit (Ambion, Austin, TX) following the recommended protocol. DNA samples (0.5 μg) 
were treated with sodium bisulphite using the EZ DNA methylation Gold kit (Zymo), and 
bisulphite-treated DNA was applied to an Illumina Infinium HumanMethylation27 BeadChip for 
DNA methylation profiling. This microarray permits the quantitative measurement of DNA 
methylation for 27,578 CpG dinucleotides spanning 14,495 genes 54.Methylation status of the 
interrogated CpG sites was determined by calculating β-values, the ratio of the fluorescent signal 
from the methylated allele to the sum from the fluorescent signals of both methylated and 
unmethylated alleles.  
2.2.3 Illumina Whole Genome Gene Expression Analysis 
Total RNA was isolated from melanoma FFPE tissues using the RecoverAllTM Total Nucleic 
Acid Isolation kit (Ambion, Austin, TX). RNA was quantified using Ribogreen RNA 
quantitation Kit (Molecular Probes, Eugene OR). Whole genome gene expression was carried 
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out on 250ng of total RNA using Illumina’s Whole-Genome DASL Assay which is specifically 
designed to work with partially degraded RNA as is obtained from FFPE tissue. The Whole-
Genome DASL Assay utilizes the whole-genome probe set of Illumina’s HumanRef-8 BeadChip 
which features up-to-date content covering more than 24,000 annotated genes derived from 
RefSeq (Build 36.2, Release 22).  
2.2.4 Statistical Analysis 
Whole genome methylation analysis: 
Infinium methylation data was analyzed using Illumina’s GenomeStudio software. Background 
intensity computed from a set of Illumina’s internal controls was subtracted from each analytical 
data point. Unsupervised hierarchical clustering was carried out using GenomeStudio software. 
Differential methylation was analyzed after applying average normalization.  
In an attempt to identify the top methylation sites in combination that can best classify 
patients, we applied a two-step feature selection procedure and selected the top 10 sites. Leave-
one-out cross validation was used to evaluate the performance of the procedure. In each iteration, 
we leave one patient out to be used as the test set, and used the rest of the patients to select a 
feature and train a classifier. First, the Wilcoxon rank sum test was applied to the training data. 
All features with a nominal p-value<0.02 are further considered in the Support Vector Machine 
(SVM) to select the top 10 feature combination that give the best prediction in the test data set.  
 
Whole genome gene expression analysis: 
The whole genome gene expression data was initially analyzed using Illumina’s GenomeStudio 
software where background subtraction and quality control checks on the data were performed. 
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The data was then imported into Biometric Research Branch (BRB) array tools 3.5.0 
(http://linus.nci.nih.gov/BRB-ArrayTools.html) for analyses. Class comparison analysis using 
paired t tests was used to identify genes that are differentially expressed in the responder and 
non-responder groups. Class prediction algorithms such as Significance Analysis for Microarrays 
(SAM) and Predictive Analysis for Microarrays (PAM) in BRB array tools were applied to 
determine whether gene expression patterns could accurately differentiate between responders 
and non-responders. False discovery rates were calculated using the Korn and Tusher methods 55, 
56. 
We also used a machine learning approach to select features that could help in 
classification of the two groups according to the method of Wang et al. 57. Sequential Minimal 
Optimization (SMO) algorithm was used with cross-validation for feature selection. Using a 
training and a validation set, the features which would be selected the maximum number of times 
when SMO is applied would represent the best features for the entire data. Subsequently, the best 
features selected are used on the entire data set to test the performance of the predictive signature 
(cross-validation). 
 
Analysis of DNA repair genes: 
We used stringent filtering criteria that excluded genes for which less than 20% of expression 
data have at least a 1.5 -fold change in either direction from gene's median value and/or if more 
than 50% of the data was missing or filtered out. All other statistical analyses were performed 
using Stata 11.1 (StataCorp, College Station, TX, USA). The Cox proportional-hazards model 
was fitted to assess the prognostic and predictive values of the methylation status of the MGMT 
and MLH1 promoters, as well as MGMT and MLH1 expression. In cases where the proportional 
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hazards assumption did not hold, non-parametric tests were utilized (Mann-Whitney and 
Wilcoxon rank sum). Only 6 patients were alive at the time of last follow-up and were censored 
accordingly. 
2.3 RESULTS 
We identified 66 patients with histologically confirmed metastatic melanoma and for whom 
tumor tissue obtained prior to initiation of alkylator-based chemotherapy was available. All 
patients had cutaneous primary melanoma and all were treated with alkylator-based therapy with 
the majority (68%) receiving single agent TMZ or dacarbazine. The median age was 51 years 
and there were 45 males and 21 females (Table 1). Patients were classified by chemotherapy 
response, 18 were considered responders and 48 non-responders. 
2.3.1 Whole genome methylation analysis 
The top 10 methylation sites associated with response were used in a classification algorithm and 
had an estimated overall accuracy rate of only 60% (Sensitivity =23% and Specificity =74%). 
Similarly, when the top 10 methylation sites were used to predict survival, the overall accuracy 
rate was 48% (Sensitivity =39% and Specificity =45%). 
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2.3.2 Whole genome gene expression analysis 
Unsupervised hierarchical cluster analysis of whole genome gene expression data did not result 
in differentiation of responders from non-responders and there were no significant differences 
between the two groups. Using machine-learning algorithm (SMO), 10 genes were selected as a 
classifier set: CDH10, HIST1H3C, FLJ25770, DDIT4L, LRRN3, BHLHB5, EFCBP1, ZNF695, 
C16orf59, C19orf59. This 10-gene set had a sensitivity of 83% and a specificity of 94% for 
identifying the response phenotype with an Area under the ROC curve of 0.917. 
 
2.3.3 Analysis of DNA repair genes 
The analysis was then restricted to the gene expression and promoter methylation of DNA repair 
genes involved in the MGMT, MMR and Base Excision Repair pathways, the 3 canonical DNA 
repair pathways known to be involved in the repair of TMZ-induced DNA damage. Using PAM 
analysis, only 52 genes passed the filtering criteria and MLH1 was the only gene that predicted 
survival at the 0.01 significance level (p=0.0092). Increased MLH1 expression was associated 
with a hazard ratio for death of 0.694 (31% decrease in the risk of death). A Cox proportional 
hazard model was fitted using MLH1 expression as a continuous variable and identified a high 
risk and low risk group with highly significant p-value of 0.0099 (adjusted for multiple 
comparisons using the Bonferroni method). 
We subsequently dichotomized MLH1 expression into 2 groups: high for MLH1 
expression above the mean expression value for the entire cohort and low for MLH1 expression 
below the mean. Using the log-rank test, we confirmed that high MLH1 expression was 
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significantly associated with improved survival (Figure 2). Although in this dataset, response to 
chemotherapy was significantly associated with survival (p=0.007). A logistic regression model 
that adjusted for survival still identified a significant association between high MLH1 expression 
and objective response to chemotherapy (p=0.045). High MLH1 expression had a sensitivity of 
63% and specificity of 81% in predicting survival for an Area under the ROC curve of 74%. 
We then investigated the regulation of MLH1 by promoter methylation. We dichotomized the 
samples based on median methylation values for the entire cohort. Increased methylation of 
MLH1 promoter was independently associated with worse outcomes including decreased 
survival and resistance to chemotherapy (p= 0.047) (Figure 3).  MLH1 methylation and 
expression were significantly correlated with lower mean expression in patients with 
hypermethylated MLH1 promoter and a higher mean expression in patients with hypomethylated 
MLH1 promoter (p=0.001) (Figure 4). The predictive value of both MLH1 gene expression and 
promoter methylation were assessed independently using ROC curves and have similar 
sensitivities and specificities indicating that they both reflected the same predictive information. 
We also examined the role of MGMT promoter methylation and gene expression. Neither of 
these correlated with response or survival (Figures 5 and 6). Given the sequential nature of the 2 
pathways, a model integrating their effects on response and survival was tested and revealed that 
MGMT was not informative and MLH1 continued to be a powerful predictor of outcome. 
MLH1 promoter methylation was used as part of a CpG Island Methylator Phenotype (CIMP) 
developed for colorectal and gastric carcinoma utilizing DNA methylation data in five CIMP-
specific gene promoters [CACNA1G, CDKN2A (p16), CRABP1, MLH1, and NEUROG1] 58. 
Since these data were available from our patient population, we derived a CIMP index, which 
results in values from 0 (indicating no promoter methylation for any gene) to 5 (indicating 
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promoter methylation at all the genes). The cutoff of ≥4 out of 5 promoters being methylated was 
used in other cancer types but was not associated with response or survival in our melanoma 
cohort. However, a CIMP value of 0 (no methylation at the 5 promoters) was in fact associated 
with better survival (p<0.0001). 
2.4 DISCUSSION 
In this study, we have shown that the promoter methylation and gene expression of MLH1 are 
important predictors of survival and response to alkylator-based chemotherapy in metastatic 
melanoma.  Gene expression profiling provides a powerful means of tumor classification and has 
been used to identify previously undetected subtypes of cutaneous melanoma 59, to identify a 
gene expression pattern that correlates with BRAF mutation status in melanoma cell lines 60, and 
to characterize the progression of melanoma 61. More recent studies have examined pretreatment 
gene expression profiles within cell lines and correlated results with treatment outcome 62-64. 
Efforts in the field of melanoma have largely been restricted to candidate genes and not a global 
genome-wide approach. A recent study by Augustine et al. represents, to date, the most 
comprehensive approach where the investigators studied a panel of 26 human-derived melanoma 
cell lines in an effort to evaluate the relationship between temozolomide sensitivity, DNA 
mismatch repair (MMR) efficiency, and gene expression patterns 65.  
The 10-gene signature identified by us in this report performed reasonably well for the 
prediction of a chemotherapy response phenotype. However, the False Discovery Rate (FDR) for 
the genes involved ranged from 0.23-0.72, which raises concern about its robustness and requires 
a larger cohort to confirm its validity.  
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Hypermethylation of CpG sites, often in promoter regions or CpG islands of tumor-
related genes, plays a role in the development and progression of many cancers 50, 66-70. The 
detection of hypermethylated genes in tumors has become an important approach to the 
assessment of candidate tumor-related gene inactivation as well as to disease prognostication and 
prediction of response to therapy 71-73. The study by Shen et al. on the correlation of DNA 
methylation with gene expression analysis using the NCI-60 cancer cell line panel revealed that 
DNA methylation correlated with gene expression in most cases. This approach illustrates the 
added advantage of being able to detect genes with low baseline expression as well as genes with 
multiple alternate transcripts, two situations that are particularly problematic in gene expression 
profiling. In addition this provides the opportunity to distinguish an epigenetically silenced state 
from a physiologic transient decrease in gene expression 74.  
Several studies have focused on candidate genes such as MGMT and RASSF1A in cell 
lines as well as primary tumors 75-78. A pivotal study by Hegi et al. established the promoter 
methylation status of MGMT as a predictive biomarker for survival in patients with glioblastoma 
multiforme treated with temozolomide 50. A study by Mori et al. reported that patients with 
hypermethylation of the RASSF1A and RAR-ß2 in DNA from the serum of melanoma patients 
receiving biochemotherapy had significantly worse overall survival than patients with no 
methylated genes 79.  
The role of MGMT promoter methylation and/or expression appears to be limited in 
predicting the outcomes of chemotherapy in metastatic melanoma. Recent reports indicate a role 
for MGMT in predicting toxicity but not response to chemotherapy 80, 81. This is not surprising 
given the fact that the MMR pathway is an obligate pathway to apoptosis after alkylator-induced 
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DNA damage and its deficiency is likely to be a more relevant mechanism of chemotherapy 
resistance (Figure 1). 
In MMR, the MutSα-complex heterodimer (MSH2, MSH6) binds to the mismatch and 
recruits an additional heterodimer, the MutLα complex (MLH1, PMS2). As the MMR system 
does not remove O6-meG, but the nucleotides opposite to it, thymine is inserted again. This 
results in futile repair attempts and subsequent activation of a signaling cascade, resulting in cell 
cycle arrest in the G2 phase followed by apoptosis, mitotic catastrophe, or a senescence-like state 
82.  
MMR deficiency therefore results in clinical drug resistance. Biallelic inactivation of 
MLH1 because of a SNP at the acceptor splice site of intron 15 may lead to the disruption of 
MMR in melanoma 83. Loss of mismatch repair due to methylation of the MLH1 gene promoter 
results in resistance to cisplatin in cell lines in vitro and in human tumor xenografts in vivo 71. 
Methylation of the MLH1 gene promoter is observed in many tumor types 84, 85 and loss of MLH1 
expression is associated with clinical drug resistance in ovarian cancer 86. 
In this study, our findings indicate that MLH1 expression, presumably resulting in a 
functional MMR, is associated with improved chemotherapy outcomes in metastatic melanoma. 
We have also identified promoter methylation of MLH1 to be the most likely mechanism through 
which MLH1 is being silenced.  
Our results are of particular relevance on several fronts:  
1- they suggest a role of the MMR system in melanoma resistance to alkylating agents. 
2- they identify epigenetic silencing as the alteration underlying such resistance and 
therefore offer the opportunity of therapeutic interventions. Specifically, this epigenetic change 
can be reversed pharmacologically with agents such as decitabine or HDAC inhibitors. In fact, in 
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an ovarian cancer cell line model, Barvaux et al. showed that cells in which MMR is 
epigenetically silenced are resistant to TMZ even after MGMT depletion while re-expression 
with decitabine leads to the reversal of resistance 21. 
3- they offer the opportunity of developing a simple and reproducible predictive 
biomarker of chemotherapy response in melanoma. Specifically, promoter methylation of MLH1 
is a DNA-based test that is more easily reproducible than mRNA expression even in FFPE tumor 
tissue preserved for years (as in our patient population).  
The conclusions of our study are limited by the relatively modest sample size however 
the results are quite consistent with a well-understood mechanistic model of chemotherapy 
resistance. Our findings will require validation in an independent cohort, where ideally data can 
be collected prospectively to avoid biases inherent to retrospective studies. 
2.5 CONCLUSION 
In this study, we have demonstrated the role of the MMR gene MLH1 as a predictor of survival 
and response to alkylator-based chemotherapy in metastatic melanoma. A particularly useful 
application of our strategy is the identification of a subset of patients in whom an epigenetically 
modifiable molecular alteration (namely promoter methylation of MLH1) offers the potential to 
be transformed into one that is more favorable to chemotherapy thereby abrogating drug 
resistance. This hypothesis is being actively investigated in patients with metastatic melanoma 
treated on a prospective Phase I/II clinical trial with the epigenetically active agent, decitabine, in 
combination with temozolomide at the University of Pittsburgh Cancer Institute (UPCI 07-008). 






Figure 1. DNA Repair Pathways 
Three canonical DNA repair pathways are involved in reversing the DNA damage induced by 
Temozolomide (TMZ).  TMZ methylates the DNA backbone at specific residues such as the O6- 
position of guanine (resulting in O6-methylguanine (O6-meG), N7-methylguanine (N7-meG), and 
N3-methyladenine (N3-MeA). N7-meG and N3-meA DNA adducts are rapidly and efficiently 
repaired by the base excision repair (BER) pathway, and normally contribute little to TMZ-
induced cell death. MGMT (O6-meG DNA methyltransferase) removes the O6-alkylguanine 
DNA adduct and restores the guanine to normal. Mismatch Repair (MMR) recognizes the mis-
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pair formed during replication of an un-repaired O6-MeG lesion. MMR attempts to repair this 
mismatch but fails resulting in futile cycles of repair that then initiate cell death. 
 
Figure 2 MLH1 expression and survival 
Kaplan-Meier Survival Plots with significantly improved survival in patients with high MLH1 
Expression. 
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Figure 3 MLH1 methylation and survival 
Kaplan-Meier Survival Plots with significantly improved survival in patients with low MLH1 
Promoter Methylation. 
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Figure 4 MLH1 expression in relation to methylation status of MLH1 
MLH1 promoter unmethylated = 0 and methylated =1. Box plot is centered around mean, p-value 
of 0.001 obtained by one-way ANOVA. 
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Figure 5 MGMT expression and survival 
Kaplan-Meier Survival Plots showing no difference in survival based on MGMT Expression. 
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Figure 6 MGMT methylation and survival 
Kaplan-Meier Survival Plots showing no difference in survival based on MGMT Promoter 
Methylation. 
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2.7 TABLES 
Table 1 Characteristics of Study Population 
 N Median (Range) 
Age (years) 66 51 (23-90) 
 N (%) 
Gender   
Female 21 32 
Male 45 68 
Response   
Responder 18 27 
Non responder 48 73 
   
Types of chemotherapy   
Single agent TMZ 29 44 
TMZ-based combination 3 5 
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3.0  EPIGENETIC MODULATION OF DNA REPAIR: PHASE I/II STUDY OF 
DECITABINE (DAC) COMBINED WITH TEMOZOLOMIDE (TMZ) IN METASTATIC 
MELANOMA 
3.1 INTRODUCTION 
Melanoma incidence is rapidly increasing throughout the world. Based on American Cancer 
Society estimates, in 2010 there will be approximately 68,130 new cases of invasive melanoma 
in the United States 87. The disease will be responsible for over 8,700 deaths in 2010. Prognosis 
for patients with metastatic disease remains poor, with a 5-year survival rate of 6% and a median 
survival of approximately 6 months 11. The first randomized Phase III clinical trial to ever result 
in improved survival was reported in 2010 with the anti-CTLA4 antibody, ipilimumab, with a 
median overall survival of 10.9 months while the objective response rate was only 10.9% 17. 
Small molecule inhibitors of the mutated BRAF gene have achieved unprecedented response 
rates approaching 80% and are likely to lead to improved survival as well. However, this 
approach is limited to patients that harbor the BRAF mutation (40-50% of melanoma patients) 
and has not resulted in durable responses, with median duration of response that is approximately 
6 months 18.  
Alkylating agents remain an important therapeutic option for patients with metastatic 
melanoma that are either wild-type for BRAF or that progress on ipilimumab or BRAF-directed 
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therapy. Dacarbazine is the only chemotherapeutic agent in current use that is approved by the 
US FDA for the treatment of metastatic melanoma, with modest response rates not exceeding 7% 
in large Phase III trials 33, 88, 89. Temozolomide (TMZ) is spontaneously converted to the same 
active metabolite 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) after oral 
administration and has shown clinical activity at least equivalent to dacarbazine in melanoma 
when given in standard schedules 33.  
MTIC directly methylates DNA at the N7 and O6 positions of guanine (70% and 6% of base 
lesions, respectively), and the N3 position of adenine (9%). The O6-methylguanine (O6-meG) 
base lesion is considered to be primarily responsible for the cytotoxicity of TMZ and is directly 
reversed by the DNA repair protein, O6-methylguanine-DNA-methyltransferase (MGMT) 
leading to cell survival and clinical drug resistance 19. Low-dose, extended-schedule TMZ has 
been shown to deplete MGMT but was not shown to improve patient outcomes when compared 
to standard dacarbazine 90. 
However, the cytotoxicity of the O6-meG lesion results only when a functional DNA 
mismatch repair (MMR) pathway exists to recognize the damage and initiate cell death. MMR 
deficiency is often induced by epigenetic silencing of key MMR genes, such as MLH1, through 
hypermethylation of the promoter region. Promoter hypermethylation can be reversed with 
hypomethylating agents (such as decitabine (DAC)) leading to re-expression of MLH1 and 
sensitization of tumors to TMZ 21. We hypothesized that the combination of TMZ and DAC will 
effect dual modulation of DNA repair through the depletion of MGMT and re-expression of 
MMR proteins. To test this hypothesis, we conducted a Phase I/II clinical trial of the 
combination of extended-schedule TMZ and DAC to reverse melanoma resistance to TMZ. This 
is to our knowledge the first attempted dual DNA repair inhibition approach in the clinic. 
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3.2 PATIENTS AND METHODS 
3.2.1 Study Design 
The study was a non-randomized open-label Phase I/II clinical trial conducted at a single 
institution, the University of Pittsburgh Cancer Institute. The objectives of the Phase I part were: 
a) to determine the safety, tolerability, and recommended Phase II dose (RP2D) of the 
combination of extended schedule TMZ and DAC; b) to determine the pharmacokinetics (PK) of 
the combination of TMZ and DAC; c) to determine, in peripheral blood mononuclear cells 
(PBMC) and tumor tissue, the pharmacodynamic (PD) effects of the combination of TMZ and 
DAC on promoter methylation and expression of selected genes. The objectives of the Phase II 
part were: a) to determine the efficacy, as measured by overall response rate, of the combination 
of extended schedule TMZ and DAC given at the RP2D to patients with metastatic melanoma; b) 
to determine the safety profile of the combination of TMZ and DAC at the RP2D; c) to 
determine the overall survival (OS) and progression-free survival (PFS) of patients with 
metastatic melanoma treated with TMZ and DAC. The study (UPCI 07-008, NCT00715793 on 
clinicaltrials.gov) was reviewed and approved by the University of Pittsburgh Institutional 
Review Board (IRB) and all patients signed informed consent. The study was jointly funded by 
Eisai, Inc. and Schering Plough Research Institute (now Merck) and supported by the University 
of Pittsburgh Cancer Institute and the Melanoma and Skin Cancer Program. The investigators 
designed, conducted, and analyzed the study independently. Toxicity assessments were 
performed using CTCAE 3.0 and efficacy assessments were according to RECIST 1.0. 
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3.2.2 Patients 
Eligible patients had to have non-resectable Stage IIIB or stage IV metastatic melanoma that 
have not received prior therapy or that have progressed despite prior therapies.  Prior biological 
therapy was allowed, one line of prior chemotherapy was allowed as long as it did not include 
TMZ or dacarbazine. Patients had to have an ECOG performance status of 0, 1 or 2, and 
adequate bone marrow, renal, and hepatic function. Patients with treated and stable brain 
metastases were allowed. 
3.2.3 Chemotherapy Regimen 
Decitabine was administered at the specified dose level, intravenously, daily 5 days a week for 
the first 2 weeks of a 6-week cycle. TMZ was administered orally at 75 mg/m2 daily for 4 weeks 
starting on week 2 of a 6-week cycle (Figure 7). The dose of TMZ was constant on both the 
Phase I and Phase II portions of the study. In the Phase I portion, two doses of DAC were used: 
0.075 mg/Kg on dose level 1 (DL1) and 0.15 mg/Kg on dose level 2 (DL2) (Table 2). Dose 
delays and dose modifications for toxicity were allowed as specified in protocol. 
3.2.4 Statistical Considerations 
The Phase I part of the study sought to determine the maximum tolerable dose (MTD)/ R2PD 
using a modified version of the standard "up and down" (3+3) dose-finding method using cohorts 
of 3 patients. At the start of the trial, three patients were to be placed at dose level 1. Only dose-
limiting toxicities (DLT) observed in a patient during the first cycle were used for the dose 
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escalation decisions.  Patients were considered evaluable for toxicity if they received 1 complete 
cycle of therapy, or if they did not complete the cycle secondary to toxicities. Non-evaluable 
patients were replaced. Only 2 doses levels were to be explored. If DL2 was considered 
tolerable, dose escalation was to stop and DL2 declared MTD/R2PD. 
The Phase II part of the study was designed in 2 stages using a Simon two-stage design. The 
treatment would be considered worthy of further study if the response rate were 21% or greater. 
In this circumstance, a risk greater than 15% (β, type II error) for incorrectly determining that the 
treatment is not worthy of further study is regarded as unacceptable. On the other hand, we 
would conclude that the treatment is unworthy of study if the response rates were 7% or less; in 
this circumstance, a risk greater than 10% (α, type I error) for declaring an unpromising 
treatment to be worthy of further pursuit is regarded as unacceptable. Subject to these 
constraints, the two-stage design is satisfied by the following criteria: 
a) In the first stage, patients will be accrued and treated until there are 14 evaluable patients. 
The 6 patients accrued at the MTD/R2PD during the phase I part were to be included in the first 
stage.  If no responses are observed, the study will terminate. 
b) If 1 or more responses are observed, the study will proceed to a second stage, accruing an 
additional 20 evaluable patients. 
d) If the second stage is completed with a total of 5 or more responses among the 34 
evaluable patients, then it will be concluded that the treatment is deserving of further study. 
e) Conversely, if the study terminates at the first stage, or if the responses total 4 or fewer, 
the treatment will not be recommended for further study. 
Details of pharmacokinetic and pharmacodynamic sampling and results are reported separately 
in Section 4.0. 
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3.3 RESULTS 
A total of 39 patients were enrolled on the study. The Phase I part of the study enrolled three 
patients to DL1, however, one patient did not complete cycle 1 secondary to disease progression 
and was replaced. No DLTs were observed and dose escalation proceeded to DL2. Six patients 
were enrolled on DL2 and no DLTs were observed. DL2 was therefore declared the MTD/R2PD 
and enrolment to the Phase II part started. The six patients treated on DL2 were analyzed with 
the Phase II population. To be evaluable for efficacy patients had to complete 2 full cycles of 
therapy. Non-evaluable patients were replaced. A total of 35 patients were enrolled on the Phase 
II part, two were not evaluable for efficacy.  
Patient characteristics are summarized in Table 3. The overwhelming majority of patients 
had metastatic disease and most had poor prognostic features including: M1c disease (31, 88%), 
brain metastases (42%), male gender (70%), and PS of 1 (70%). The median age was 63.3 years 
(range 36-78). 51% of patients had received prior immunotherapy whereas only 23% had 
received prior chemotherapy. The median number of cycles received was 2, 20% of patients 
received more than 4 cycles; the total number of administered cycles was 101. All patients were 
off-study at the time of data cutoff on December 31, 2010. Of note, only 2 patients went on to 
receive ipilimumab subsequently, both of whom had completed 36 weeks of therapy on this trial; 
and none of the patients received a BRAF inhibitor. 
3.3.1 Toxicity 
Hematologic toxicities were common and represented all grade 3 and 4 toxicities observed 
(Table 4). Neutropenia was the most common, occurred typically in weeks 4-5 and recovered in 
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1-2 weeks. Neutropenic fever occurred in only 2 instances, which were managed successfully 
with antibiotics and growth factor support. Grade 3/4 neutropenia lasted more than 7 days in 6 
out of 34 patients evaluable for toxicity on the Phase II part for an acceptable DLT rate of 18%. 
Temozolomide dose modifications allowed patients to continue being treated on the study, only 2 
patients ultimately discontinued therapy secondary to toxicity. Growth factor support was only 
used in patients with neutropenic fever and otherwise was not allowed. Common non-
hematologic toxicities were grade 1/2 fatigue (59%), and grade 1 nausea (54%) (Table 4). 
3.3.2 Efficacy 
Thirty-three patients were evaluable for response. Of those, one patient had a complete response 
(CR); four had confirmed partial responses (PR), 14 had stable disease (SD) and 14 had 
progressive disease (PD) (Table 5). The overall response rate (ORR) was 15.2% [90% CI, 6-
29%]. The disease control rate (DCR) comprised of CR+PR+SD was 18/33= 58% [90%CI, 39-
70%] (Figure 8). The median progression-free survival (PFS) was 2.8 months [95% CI, 2.6-5.6 
months], and the 6-months PFS rate was 26% [95% CI, 15-46%] (Figure 10).  The median 
overall survival (OS) has not been reached but was estimated at the data cutoff point to be 15.2 
months [95% CI, 11.7-]. The 1-year OS rate was 63% [95% CI, 48-83%] (Figure 9). 
3.4 DISCUSSION 
In this Phase I/II study, DAC was administered safely in combination with TMZ in patients with 
metastatic melanoma at biologically relevant doses. The combination of DAC and TMZ 
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achieved improved clinical efficacy in metastatic melanoma patients as compared to single-agent 
TMZ: the study reached the pre-specified primary endpoint for efficacy based on an objective 
response rate of 15%, but also modestly improved median PFS and more than doubled the 
median OS (15.2 months) and the 1-year OS survival rate (63%). 
The role of chemotherapy with alkylating agents has evolved in the treatment of metastatic 
melanoma. TMZ, given in a standard schedule (150-200 mg/m2 daily x 5 days every 28 days), 
was compared to dacarbazine in a large Phase III trial conducted in the UK by Middelton, et al. 
15. In the intent-to-treat population, median OS was 7.7 months for patients treated with TMZ 
and 6.4 months for those treated with dacarbazine. Median PFS time was significantly longer in 
the TMZ-treated group (1.9 months) than in the dacarbazine-treated group (1.5 months) 
[p=0.012; HR, 1.37; 95% CI, 1.07-1.75]. No major difference in drug safety was observed. TMZ 
was well tolerated and produced a noncumulative, transient myelosuppression late in the 28-day 
cycle. The median PFS of 2.8 months observed in our study was modestly improved over that 
observed with single-agent TMZ both as delivered in the standard schedule (Middleton 33, 1.9 
months, 1 sample log rank test p-value <0.0001) and in an extended schedule (EORTC 90, 2.3 
months, 1 sample log rank test p-value <0.0001). The improvement we observed in median 
overall survival (OS) was striking. Specifically, the median OS observed in the Middleton paper 
for standard schedule TMZ was 7.9 months. The observed median OS in this study (15.2 
months) was significantly higher than 7.9 months (1 sample log rank test p-value=0.003). The 
median OS was also significantly higher than 9.15 months observed in the EORTC trial for 
extended scheduled TMZ (1 sample log rank test p-value=0.02). 
The modulation of DNA repair mechanisms has been the subject of intense investigation 
given its potential to reverse chemotherapy resistance and improve the efficacy of alkylators. 
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MGMT was one of the first DNA repair mechanisms that offered an opportunity for modulation. 
MGMT is a ubiquitously expressed and highly conserved DNA repair protein that is vital in the 
maintenance of DNA integrity, and is a well recognized mechanism of alkylator resistance. 
Unlike other DNA repair mechanisms, MGMT does not activate a pathway but is a single protein 
that recognizes and repairs DNA damage through its specificity for O6- substituted purines 91. 
O6-meG analogs were developed with the goal of depleting MGMT by presenting it with decoy 
base lesions that are themselves devoid of toxicity. However, extensive experience with the 
intravenous O6-benzyl guanine (O6-beG) in early phase trials confirmed that O6-beG leads to 
increased myelosuppression that is not paralleled by an increase in efficacy in melanoma, soft 
tissue sarcoma, multiple myeloma, and glioblastoma multiforme (GBM) 92-102. 
O6-(4-bromothenyl)-guanine (lomeguatrib, Patrin®) is a new generation of O6-meG analogs 
that is orally bioavailable. In a Phase I trial in patients with melanoma conducted at our 
institution, lomeguatrib was administered with dacarbazine daily for 5 days and escalated to 
twice daily for 10 days. The MTD of dacarbazine was only 400 mg/m2, <50% of the standard 
(800-1000 mg/m2) clinical dose 20. In a recapitulation of the O6-BG experience, no improvement 
in the efficacy of dacarbazine was observed although a formal phase II trial is yet to be 
conducted. 
A low dose extended-schedule administration of TMZ offered more sustained (although less 
profound) MGMT inhibition while the total delivered dose of the alkylating agent exceeded the 
standard clinical doses usually administered over 5-day regimens 103. This strategy was the basis 
for a large EORTC randomized Phase III trial in metastatic melanoma where 859 patients were 
randomized to receive TMZ 150mg/m2/day orally days 1-7 repeated every 14 days (‘week on-
week off’) or dacarbazine 1000mg/m2 IV every 21 days. The preliminary results reported at the 
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European Society of Medical Oncology (ESMO) Annual Congress revealed a minor increase in 
response rates (10 vs. 14%), although the extended schedule TMZ did not impart any survival 
benefit (median OS 9.36 months vs. 9.13 months) 90. 
The lack of clinical efficacy observed with the single-pathway inhibition of MGMT could 
be, in part, due to the dependence of this pathway on a functional MMR system for cytotoxicity 
to occur 104. MGMT and MMR have contrasting effects on DNA O6-MeG. The former provides 
an efficient mechanism of repair. MMR in contrast does not remove the methylated base but 
transforms the latter into a lethal lesion and activates the apoptotic pathways. If MMR is 
deficient the O6-MeG lesion can persist without leading to apoptosis and consequently the cell 
will survive. MMR deficiency occurs primarily through epigenetic silencing of the key MMR 
genes by promoter methylation. This was shown to be a reversible process through treatment 
with epigenetic agents such as Decitabine (DAC). DAC is a DNA-methyltransferase-1 (DNMT-
1) inhibitor that is approved for the treatment of myelodysplastic syndromes (MDS) and if used 
at low doses leads to significant DNA hypomethylation 105. 
DAC has been reported to induce hypomethylation in tumor xenografts and this was 
associated with increased sensitivity to carboplatin 71. A recently reported phase I clinical trial of 
DAC in combination with carboplatin determined the phase II recommended dose to be DAC IV 
at 90 mg/m2 (day 1) followed by carboplatin IV at an AUC 6 (day 8) every 28 days. DAC 
produced a reduction in DNA methylation equivalent to or greater than that observed in the 
xenograft model 106. Treatment with DAC in melanoma cells has also been reported to lead to re-
expression of products of epigenetically silenced genes such as the MMR protein hMLH1 and 
therefore lead to a proficient MMR system sensitizing melanoma cells to the cytotoxic effects of 
chemotherapy 32, 71. 
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In this Phase I/II study we used a dose and schedule of DAC comparable to a Phase I trial of 
DAC in combination with high-dose Interleukin-2 that led to significant hypomethylation in 
patients with metastatic melanoma 107. Based on this experience, where doses as low as 0.10 
mg/kg led to hematologic DLTs, our trial was designed to explore 2 dose levels –one lower 
(0.075 mg/kg), and one higher (0.15 mg/kg) than this prior dosage. DAC at 0.15 mg/kg was well 
tolerated and led to the expected incidence of grade 4 neutropenia ~40-50%. This neutropenia 
lasted more than 7 days in only 18% of patients, and was associated with neutropenic fever in 2 
patients.  In general patients were asymptomatic and the neutropenia was reversible without the 
use of growth factors. Full doses of TMZ were administered and dose modifications were 
infrequent but allowed most patients to complete therapy safely. Only 2 patients discontinued 
therapy secondary to toxicity, one for neutropenic fever and the other for requiring >2 dose 
reductions. 
The overall survival benefit in this study is unlikely to be due to subsequent therapy, since 
only ipilimumab is known to improve OS in patients with metastatic melanoma and only 2 of our 
patients ever received ipilimumab, both after completing 9 months of therapy with TMZ on our 
study. In order to account for this factor, we examined the 1-year OS rate, which was 
significantly higher at 63% [95% CI, 48-83%] than the landmark of 25% established by the Korn 
meta-analysis of prior phase II trials 34. 
Patient selection in a non-randomized Phase II trial limits the extrapolation of results such as 
these; however it should be noted that our patient population exhibited several features that 
would have resulted in poorer outcomes. For instance, both the UK and EORTC trials excluded 
patients with CNS metastases while 42% of our Phase II patients had prior evidence of CNS 
metastases. Also, in the Korn meta-analysis, the presence of visceral disease (M1c) and ECOG 
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PS>0 were adverse prognostic factors. Visceral disease was present in 88% of our patients and 
70% had PS of 1 (Figure 11). 
3.5 CONCLUSION 
We have conducted a Phase I/II clinical trial with DAC in combination with extended-schedule 
TMZ in patients with metastatic melanoma which is, to our knowledge, the first attempted dual 
DNA repair inhibition approach to date in the clinic. We have established a recommended Phase 
II dose of the combination that led to improved clinical outcomes including response rate, 
clinical benefit rate, median PFS and median OS, and we believe that this data warrants further 
evaluation in a randomized setting. 






Decitabine is given intravenously at the specified dose level 5 days/week for the first 2 weeks; 
Temozolomide is given orally at 75 mg/m2 daily starting on Day 8 for a total of 4 weeks; week 6 
is a rest week. The arrows depict the days on which pharmacokinetic studies were performed 
(Days 1 and 8) and on which PBMC and optional serial tumor biopsies were collected for 
pharmacodynamic analyses. 
Figure 7. Treatment Administration Schedule 
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Figure 8. Waterfall Plot- Best Overall Response 
Best Overall Response by RECIST 1.0 is depicted as percent change on the y-axis. Every bar 
represents one patient. The horizontal dotted lines represent the RECIST limits for progression 
(+20%) or objective response (-30%). Complete Response (CR) is represented in blue, Partial 
Response (PR) in green, Stable Disease (SD) in red, and Progressive Disease (PD) in black. Note 
that one patient that had SD by RECIST was considered PD (black) as there was evidence of 
new CNS metastases on evaluation. 
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Figure 9. Kaplan-Meier Curve of Overall Survival with 95% CI.  
 
Figure 10. Kaplan-Meier Curve for Progression-Free Survival with 95% CI 










Current data presented in context of the meta-analysis by Korn et al., the arrow 
indicates the data point from the current study. 
Figure 11. Current Data in the Context of Korn Model 




Table 2. Phase I Dose Levels and Dosing Schedule 
Phase I Week 1 2 3 4 5 6 
Level 0 TMZ PO 
 (mg/m2/day) 
- 75 75 75 75 - 
 Decitabine IV 
 (mg/kg qdx5) 
0.0375 0.0375 - - - - 
Level 1 TMZ - 75 75 75 75 - 
 Decitabine 0.075 0.075 - - - - 
Level 2 TMZ - 75 75 75 75 - 
 Decitabine 0.15 0.15 - - - - 
Phase II Week 1 2 3 4 5 6 
 TMZ PO  - 75 75 75 75 - 
 Decitabine IV 0.15 0.15 
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Table 3. Patient Baseline Characteristics 
  N Median (Range) 
Age (Years)  39 63.3 (36.2-77.4) 
  N (%) 
Gender Female 12 31 
 Male 27 69 
Stage Stage IIIC 2 5 
 Stage IV-M1a 4 10 
 Stage IV-M1c 33 85 
ECOG Performance Status 0 10 26 
 1 28 71 
 2 1 3 
Any Prior Treatment Chemotherapy 9 23 
 Immunotherapy 20 51 
CNS Metastases Present 16 42 
 Absent 23 58 
 




Table 4. Adverse Events and Number of Patients by Worst Grade (All Cycles) 
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Table 5. Objective Response by RECIST 
 N % 
CR: Complete Response 1 3 
PR: Partial Response 4 12 
SD: Stable Disease 14 42 
PD: Progressive Disease 14 42 
Overall Response (CR+PR) 5 15% 
Clinical Benefit Rate (CR+PR+SD) 19 57% 
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4.0  PHARMACOKINETICS AND PHARMACODYNAMICS OF THE 
COMBINATION OF DECITABINE (DAC) AND TEMOZOLOMIDE (TMZ) IN 
PATIENTS WITH METASTATIC MELANOMA 
4.1 INTRODUCTION 
Chemotherapy has limited clinical benefits in the treatment of patients with metastatic melanoma 
12. Chemotherapy resistance is primarily mediated by DNA repair mechanisms 37. Mounting 
evidence points to epigenetic silencing of gene expression of key DNA repair genes as 
mechanisms of resistance. Specifically, down-regulation of mismatch repair (MMR) proteins 
MLH1, MSH2 and MSH6 has been linked to chemotherapy resistance 71, 108. Epigenetic silencing 
through promoter methylation is a dynamic process that is amenable to modulation using agents 
such as DNA methyltransferase-1 (DNMT-1) inhibitor decitabine (2’,5’-deoxy-azacytidine, 
DAC) 46, 71. DAC is FDA-approved for the treatment of myelodysplastic syndrome and has been 
shown to lead to hypomethylation resulting in re-expression of epigenetically silenced genes and 
associated clinical benefit 109. We conducted a Phase I/II clinical trial of the combination of 
extended-schedule TMZ and DAC (UPCI 07-008) to reverse melanoma resistance to TMZ. We 
hypothesized that the combination of TMZ and DAC will effect dual modulation of DNA repair 
through the depletion of MGMT and re-expression of MMR proteins, resulting in improved 
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clinical response. This is to our knowledge the first attempted dual DNA repair inhibition 
approach in the clinic.  
In this translational corollary, we report the results of pharmacokinetic and 
pharmacodynamic analyses performed on blood and tumor tissues obtained from patients 
enrolled on UPCI 07-008. 
4.2 PATIENTS AND METHODS 
4.2.1 Study Design 
The study was a non-randomized open-label Phase I/II clinical trial conducted at a single 
institution, the University of Pittsburgh Cancer Institute. The objectives of the Phase I part were: 
a) to determine the safety, tolerability, and recommended Phase II dose (RP2D) of the 
combination of extended schedule TMZ and DAC; b) to determine the pharmacokinetics (PK) of 
the combination of TMZ and DAC; c) to determine, in peripheral blood mononuclear cells 
(PBMC) and tumor tissue, the pharmacodynamic (PD) effects of the combination of TMZ and 
DAC on promoter methylation and expression of selected genes and correlate these with 
response. The objectives of the Phase II part were: a) to determine the efficacy, as measured by 
overall response rate, of the combination of extended schedule TMZ and DAC given at the 
RP2D to patients with metastatic melanoma; b) to determine the safety profile of the 
combination of TMZ and DAC at the RP2D; c) to determine the overall survival (OS) and 
progression-free survival (PFS) of patients with metastatic melanoma treated with TMZ and 
DAC. The study (UPCI 07-008, NCT00715793 on clinicaltrials.gov) was reviewed and approved 
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by the University of Pittsburgh Institutional Review Board (IRB) and all patients signed 
informed consent. The study was jointly funded by Eisai, Inc. and Schering Plough Research 
Institute (now Merck) and supported by the University of Pittsburgh Cancer Institute and the 
Melanoma and Skin Cancer Program. The investigators designed, conducted, and analyzed the 
study independently. Toxicity assessments were performed using CTCAE 3.0 and efficacy 
assessments were according to RECIST 1.0. 
4.2.2 Patients 
Eligible patients had to have non-resectable Stage IIIB or stage IV metastatic melanoma that 
have not received prior therapy or that have progressed despite prior therapies.  Prior biological 
therapy was allowed, one line of prior chemotherapy was allowed as long as it did not include 
TMZ or dacarbazine. Patients had to have an ECOG performance status of 0, 1 or 2, and 
adequate bone marrow, renal, and hepatic function. Patients with treated and stable brain 
metastases were allowed. 
4.2.3 Chemotherapy Regimen 
Decitabine was administered at the specified dose level, intravenously, daily 5 days a week for 
the first 2 weeks of a 6-week cycle. TMZ was administered orally at 75 mg/m2 daily for 4 weeks 
starting on week 2 of a 6-week cycle (Figure 7). The dose of TMZ was constant on both the 
Phase I and Phase II portions of the study. In the Phase I portion, two doses of DAC were used: 
0.075 mg/Kg on dose level 1 (DL1) and 0.15 mg/Kg on dose level 2 (DL2) (Table 2). 
  50 
4.2.4 Pharmacokinetic Sampling 
Samples for pharmacokinetic analyses were performed on the first 14 patients.  On days 1 and 8, 
blood samples (5 ml) were collected using pre-chilled heparinized tubes pre-loaded with 
tetrahydrouridine (THU) (50 uL of 10 mg/mL in saline) at 0, 15, and 30 minutes (just before the 
end of infusion); and 5, 15, 30, 45, 60 minutes, 2, 4, 6, and 23 h after the end of infusion (the last 
sample is taken immediately before Day 2 decitabine administration). Blood samples were 
centrifuged immediately at 4 °C. Following centrifugation, on day 8 only, a 1-ml volume of 
plasma was transferred into a plastic tube containing 0.03 ml of 8.5% phosphoric acid followed 
by brief vortexing (for temozolomide quantitation). The rest of the plasma (all on day 1) was 
aspirated and transferred to a tube for decitabine quantitation. Samples were frozen immediately 
and stored at –80 °C until analysis. 
Temozolomide concentrations were determined according to the assay described by Kim 
et al. 110 with the following modifications. A 100 µL aliquot of the sample was placed into a 1.5-
ml microcentrifuge tube. To this, 10 µL of 1 N hydrochloric acid, and 10 µL of 1 µg/mL 
ethazolastone internal standard solution in water were added. After addition of 1 mL of ethyl 
acetate, the sample was vortexed for 10 minutes, followed by centrifugation at 4500 x g for 5 
min at room temperature. The supernatant was transferred to 12 x 75 mm glass culture tubes and 
evaporated to dryness under a gentle stream of nitrogen at 37 °C. The dry residue was taken up 
in 100 µL mobile phase by sonication for 2 min. The sample was transferred to an autosampler 
vial before injection of a 20 µL aliquot. This assay was linear, accurate (94-107%), and precise 
(coefficient of variation 0.7-3.6%) in the range of 0.1 to 20 µg/mL. Quality control samples were 
employed at 0.2, 3, and 15 µg/mL. 
  51 
Decitabine concentrations were determined by XenoBiotic Laboratories, Inc. using a 
validated method which utilizes a solid phase extraction (MCX) procedure to extract the analyte 
from 200 µL of human plasma, a reverse phase HPLC column to separate Decitabine and IS (5-
Azacytidine) from the matrix, and an LC MS/MS instrument operating with positive ESI-MRM 
mode to quantify Decitabine.  The calibration curve ranges from 1 ng/mL to 100 ng/mL for 
Decitabine. Decitabine plasma pharmacokinetic parameters were calculated from the data by 
non-compartmental methods with PK Solutions 2.0™ (Summit Research Services, Montrose, 
CO, USA).  
Temozolomide plasma pharmacokinetic parameters were calculated from the data by 
compartmental methods. An MLEM population pharmacokinetic 1-compartment, open, linear 
model with 1st order absorption was fit to the temozolomide concentration versus time data with 
the ADAPT 5 software for pharmacokinetic/pharmacodynamic systems analysis 111. The 
maximum likelihood option in ADAPT 5 was used for all estimations, and parameters were 
assumed to be log-normally distributed. Based on the schedule of chemotherapy administration 
patients were not expected to receive temozolomide as a single agent and pharmacokinetic 
sampling for temozolomide was in the presence of decitabine. To account for possible 
interactions, we used a population pharmacokinetic analysis approach in which temozolomide 
exposure was predicted using subject characteristics according to Ostermann et al. 112, based on 
sex and body surface area (BSA). Predicted temozolomide exposure was then compared to 
observed exposure to determine whether decitabine affected temozolomide exposure. 
For decitabine, only the data from patients with full pharmacokinetic profiles on both 
days were used in subsequent statistical analyses comparing the two days (Day 1 decitabine 
alone; Day 8 decitabine in the presence of temozolomide). For temozolomide, apparent 
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clearance, distribution volume and half-life data from Day 8 (after 7 days and in the presence of 
decitabine) were compared with those values predicted based on patients demographics. 
Statistical analyses for pharmacokinetic parameters and concentration values were performed 
using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL). Values were compared with a two-
tailed, paired exact Wilcoxon signed rank test, where a P < 0.05 was considered significant. 
4.2.5 Pharmacodynamic Sampling 
Pharmacodynamic sampling was performed on all accrued patients.  During cycle 1 on days 1, 8, 
15, and 29, whole blood was collected and processed to isolate peripheral blood mononuclear 
cells (PBMC). Pre-dose 10-ml blood samples were collected in Vacutainer CPT™ cell 
preparation tubes. PBMCs were isolated by centrifugation at 1500 x g for 25 minutes at room 
temperature.  Isolated PBMCs were washed twice with phosphate-buffered saline at 4o C, and 
stored at –80 ºC before further processing. Core biopsies of tumor samples were obtained from 
consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle. 
Biopsies were optional in Phase I and Phase II for all consenting subjects. 
Illumina Infinium Methylation Analysis 
DNA was isolated from melanoma tissues using ArchivePure DNA Cell/Tissue kit 
(5Prime Inc., MD, USA). DNA samples (0.5 μg) were treated with sodium bisulphite using the 
EZ DNA methylation Gold kit (Zymo), and bisulphite-treated DNA was applied to an Illumina 
Infinium HumanMethylation27 BeadChip for DNA methylation profiling. This microarray 
permits the quantitative measurement of DNA methylation for 27,578 CpG dinucleotides 
spanning 14,495 genes9. Methylation status of the interrogated CpG sites was determined by 
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comparing β-values, the ratio of the fluorescent signal from the methylated allele to the sum 
from the fluorescent signals of both methylated and unmethylated alleles.  
Illumina Whole Genome Gene Expression Analysis 
Total RNA was isolated from melanoma tissues using the PerfectPure RNA Tissue kit 
(5Prime Inc., MD, USA). RNA was quantified using Ribogreen RNA quantitation Kit 
(Molecular Probes, Eugene OR). RNA quality was also evaluated by RNA Integrity Number 
using the Agilent Bioanalyzer. Whole genome gene expression analysis was carried out using the 
Illumina HT-12 Expression BeadChip which targets more than 25,000 annotated genes with 
more than 48,000 probes derived from the RefSeq (Build 36.2, Rel 22) and UniGene databases.  
Whole genome methylation statistical analysis: 
The BeadChip images were scanned by Illumina's BeadStation system and the data were 
extracted into GenomeStudio software. Background normalization was conducted using the 
negative control signals from each well. The level of methylation (β) is a measure of the ratio 
(represented as a value between 0 and 1) of methylated-probe signal to total locus signal 
intensity. CpG loci with a detection p value of p<0.01 were not included in the analysis as a 
quality control measure. The difference in average β for each locus was calculated for every 
sample for pre and post treatment comparisons. A change in average β of 0.2 in either direction 
was considered a measureable outcome in this preliminary analysis according to quality control 
measures recommended by Illumina. 
Whole genome gene expression statistical analysis: 
Image processing and raw data extraction were performed using the Illumina 
GenomeStudio software. The data were normalized for background correction, plate scaling and 
chip-to-chip variation. The number of genes detected in each sample (probe signal significantly 
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greater than average signal from negative controls with p<0.05), was used as a measure of the 
quality of the results. Genes with a detection p value of <0.05 were not included in the analysis. 
Fold differences were calculated for all included genes for every sample. A 1.5 fold difference 
cut off in either direction was applied to each pre and post treatment comparison. 
4.3 RESULTS 
Pharmacokinetic data was available for decitabine in 15 patients and for temozolomide in 14 
patients, see Tables 6 and 7. For decitabine analysis, less than 8% of AUC0-inf was extrapolated. 
We did not observe statistically significant changes in the decitabine pharmacokinetic 
parameters between day 1 and day 8 (Figures 12 and 13). Within-subject variability for 
decitabine Cmax and clearance was 31% and 31%, respectively. Likewise, we did not observe 
statistically significant differences between observed apparent clearance and predicted apparent 
clearance for temozolomide (Figure 14). We did observe significant differences between 
observed and predicted temozolomide volume of distribution and half-life. Average 
pharmacokinetic profiles are displayed in Figure 15. 
In 6 patients, tumor tissues were available from pre- and post-treatment. Table 8 
summarizes the time points where tumor and matched PBMCs were obtained. Analysis of global 
DNA methylation revealed that treatment with DAC led to changes in DNA methylation in both 
directions, with some CpG sites becoming hypermethylated and others hypomethylated (Table 
9). Hypomethylation was more prominent and ranged from 2.4% to 10.6% of all CpG sites while 
hypermethylation ranged from 0.7% to 6.5%. Net hypomethylation occurred in 11 out of 13 
instances (85%) and was most prominent at Day 29 although it was present as early as Day 8. 
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Paired PBMC samples showed an overall net hypomethylation although this was much less 
prominent being mostly in <1% of all CpG sites and did not coincide with the degree of 
hypomethylation observed in tumors. Since there were only 6 patients, it was difficult to identify 
a pattern that correlated with clinical response. 
Global gene expression in tumor tissues was affected by treatment with DAC with genes 
being differentially expressed in either direction (Table 10). Surprisingly, the direction of most 
samples was rather towards decreased expression in most cases with decreased expression 
ranging from 0.2% up to 20.9% of all genes while increased expression ranged from 0.04% to 
not more than 2%. Interestingly, the patients that showed a net increase in expression both had 
experienced dose-limiting toxicities during cycle 1. 
We investigated the changes in promoter methylation and gene expression of all DNA 
repair genes with special emphasis on MGMT and MMR genes but there was no clear pattern in 
the changes observed (data not shown). 
We then examined the changes in promoter methylation and gene expression of p16 and 
Hemoglobin F, both implicated in the response to decitabine and clinical benefit in patients with 
MDS, AML and sickle cell disease 113-115. Treatment with DAC lead to hypomethylation of p16 
and HgF promoter regions in 5 of 6 cases (83%) and this was equally associated with increased 
gene expression as high as 8 fold in the case of HgF. 
4.4 DISCUSSION 
In this study, we have shown that DAC can be administered safely in combination with TMZ in 
patients with metastatic melanoma at biologically relevant doses. We have demonstrated that the 
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2 agents do not affect each other’s exposure using extensive PK sampling and population PK 
analysis. We also observed the pharmacodynamic effects of DAC in tumor tissues at the dose 
level that was associated with improved clinical efficacy.  
Chemotherapy with alkylating agents continues to have a role in the treatment of 
metastatic melanoma. In this Phase I/II study we used a dose and schedule of DAC comparable 
to a Phase I trial of DAC in combination with high-dose Interleukin-2 that led to significant 
hypomethylation in patients with metastatic melanoma. Based on this experience where doses as 
low as 0.10 mg/kg lead to hematologic DLTs, our trial was designed to explore only 2 dose 
levels one lower (0.075 mg/kg) and one higher (0.15 mg/kg). DAC at 0.15 mg/kg was well 
tolerated and led to the expected incidence of grade 4 neutropenia of around 40-50%.  
The combination of DAC and TMZ achieved improved efficacy and the trial reached the 
pre-specified primary endpoint for efficacy based on an objective response rate of 15%. The 
observed median OS in this study was 15.2 months and was significantly higher than 7.9 months 
(1 sample log rank test p-value=0.003). We have investigated the underlying mechanisms for this 
improved therapeutic benefit that the addition of DAC brought.  
The exposures observed in this study for temozolomide clearly agree with the exposures 
reported in the literature 112. The observed volumes of distribution did significantly differ from 
those predicted, and consequently the same applied to the half-life, which was calculated from 
clearance and volume of distribution. However, the volume of distribution does not affect the 
total exposure and the observed statistical difference is therefore not considered relevant. 
The clearance and distribution volumes for decitabine observed in this study agree 
closely with literature values 116. The different half-lives between dose level 1 and 2 are 
attributable to the longer time that plasma concentrations could be followed in patients on dose 
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level 2, resulting in capture of a more true terminal phase. Based on the PK analysis, there is no 
indication that DAC increased exposure to TMZ and therefore this benefit cannot be ascribed to 
higher alkylator effect. 
 Low doses of DAC did hypomethylate melanoma tissues at both dose levels although 
only one paired sample was available from dose level 1. This level of hypomethylation was not 
as profound as is seen with hematologic malignancies which is likely due to the smaller growth 
fraction of solid tumors as DAC requires cell division to be incorporated into the DNA and 
inhibit DNMT1. This was manifested in our study by the extent of hypomethylation since more 
profound hypomethylation at Day 29 as compared to Day 8. It is not clear why this did not result 
in significant overall increase in gene expression. However, the well documented effect of DAC 
on specific genes such as p16 and HgF, was reproduced in our data suggesting that DAC did 
achieve pharmacodynamic effects in melanoma tissue at the RP2D. 
Our hypothesis that the improvement in TMZ efficacy is mediated by the effect on DNA 
repair genes was not substantiated by the available data with the caveat that we have a very 
limited sample size and our analyses were primarily descriptive. 
4.5 CONCLUSION 
We have conducted a Phase I/II clinical trial with DAC in combination with extended-schedule 
TMZ in patients with metastatic melanoma. We have established a recommended Phase II dose 
of the combination that led to improved clinical outcomes including response rate, clinical 
benefit rate, median PFS and median OS. This improvement in clinical outcome was not 
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secondary to increased exposure of either drug and was not clearly related to changes in the 


























Figure 12. Decitabine Concentrations (Cmax) on Days 1 and 8 
Intra-individual changes of decitabine Cmax between Day 1 (decitabine alone), and Day 8 
(decitabine with temozolomide); dose level 1 (□) and dose level 2 (○); P = 0.847. 
























Figure 13. Decitabine Clearance on Days 1 and 8 
Intra-individual changes of decitabine clearance between Day 1 (decitabine alone), and Day 8 































Figure 14. Temozolomide Population Pharmacokinetics Analysis 
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Difference between predicted and observed temozolomide plasma exposure (AUC0-inf). The 
average difference was 1.6%; P = 0.855. 


























Figure 15. Concentration vs Time Profiles for Decitabine and Temozolomide 
Concentration versus time profile based on average (±SD) concentration data of 14 patients 
receiving 200 mg/m2 temozolomide (TMZ) PO with decitabine (DAC). 
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4.7 TABLES 
Table 6. Decitabine Pharmacokinetic Parameters 
 N Half-life Cmax AUC0-inf Vd CL 
  (min) (ng/mL) (ng•min/mL) (L/kg) (mL/min/kg) 
DL1 D1 4 28.2 (8.5) 47.7 (28.7) 1361 (609) 2.74 (161) 65.2 (30.9) 
DL1 D8 4 19.2 (14.6) 36.5 (18.3) 1009 (392) 2.12 (1.66) 82.3 (28.5) 
DL2 D1 11 40.5 (17.2) 98.7 (25.3) 3031 (686) 3.00 (1.27) 51.9 (11.7) 
DL2 D8 11 44.9 (19.0) 102.7 (25.6) 2918 (599) 3.44 (1.59) 53.6 (11.9) 
 
P  
D1 vs D8 
0.731 0.847 0.639 0.762 0.639 
 
Mean Standard Deviation (SD) pharmacokinetic parameters of decitabine per dose level on Day 
1 (DAC alone), and Day 8 (DAC with TMZ) derived by non-compartmental analysis. 
Table 7. Temozolomide Pharmacodynamic Parameters 
 N Ka Vd/F CL/F Half-life Cmax 
   (L) (L/h) (h) (µg/mL) 
Observed 14 3.13 (2.0) 27.3 (7.2) 11.7 (2.5) 1.60 (0.12) 5.29 (1.37) 
Predicted 14 - 32.1 (3.6) 11.6 (1.6) 1.93 (0.11) - 
 
P D8 vs 
predicted 
- 
0.0017 0.855 0.00012 - 
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Mean (Standard Deviation, SD) pharmacokinetic parameters of temozolomide on Day 8 as 
observed and calculated with a 1 compartment population model, and as predicted based on BSA 
and sex according to Ostermann et al. Cmax was visually determined from the raw data. 

















Day 1         
Tumor X X X X X X X X 
PBMC X X X X X X X X 
         
Day 8         
Tumor X X X X    X 
PBMC X X X X X X X X 
         
Day 15         
Tumor  X X X    X 
PBMC X X X X X X X X 
         
Day 29         
Tumor  X X    X X 
PBMC X X X X X X X X 
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Table 9. Changes in Global Methylation 
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Table 10. Changes in Gene Expression 
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5.0  CONCLUSION AND FUTURE DIRECTIONS 
In this dissertation I have examined the role of epigenetic regulation on chemotherapy resistance 
in metastatic melanoma. My findings can be summarized as follows: 1) the promoter methylation 
and gene expression of MLH1 are important predictors of survival and response to alkylator-
based chemotherapy in metastatic melanoma; 2) a Phase I/II clinical trial was conducted with 
DAC in combination with extended-schedule TMZ administered for patients with metastatic 
melanoma. A recommended Phase II dose of the combination was established that led to 
improved clinical outcomes including response rate, clinical benefit rate, median PFS and 
median OS; 3) The observed improvement in clinical outcome was shown to not be secondary to 
increased exposure of either drug and was not clearly related to changes in the methylation or 
expression of DNA repair genes. 
My findings from the retrospective study will require several levels of validation: 1) 
validation of the high-throughput signals with RT-PCR and possibly with immunohistochemistry 
for protein expression in the tumor tissues examined; 2) validation in a separate cohort, 
preferably not treated at our institution- discussions in that regard are already underway with 
potential collaborators; 3) prospective validation in a cohort of patients being treated with 
temozolomide or dacarbazine where clinical data can be collected real-time significantly 
reducing the sources of bias inherent to retrospective studies. It is conceivable that prospective 
clinical trials can be designed that incorporate assessment of MLH1 gene expression and 
  67 
promoter methylation as either an inclusion criterion or a stratification parameter. In the future, it 
is planned to continue examining novel integrative models that will allow the concurrent analysis 
of gene expression and promoter methylation at the whole genome level. Our current data will 
serve as a platform for such modeling approaches with plans to incorporate BRAF mutational 
testing into chemotherapy response prediction models using the novel methodology of entromics 
(this proposal has received pilot funding from the Clinical Translational Science Institute (CTSI) 
for the Basic to Clinical Collaborative Research Pilot Program (BaCCOR) in collaboration with 
Dr. Petr Pancoska). 
These findings in the Phase I/II trial of decitabine in combination with temozolomide for 
patients with metastatic melanoma are quite promising. I plan to propose a randomized 
controlled Phase II or III clinical trial to confirm our findings in patients with wild-type BRAF or 
those with BRAF mutations that have progressed on BRAF inhibitors. I am considering the 
incorporation of testing for MLH1 expression and methylation in the study design with the goal 
of validating the predictive value of MLH1 in chemotherapy response as well as move forward 
patient selection methods as means to improve outcomes in patients with metastatic melanoma. 
Finally, I plan to propose a Phase I clinical trial that adds PARP inhibition to the dual modulation 
strategy of DAC + TMZ, which we have termed “triple modulation of DNA repair”. This Phase I 
trial was already proposed to NCI-CTEP and received pilot funding from the Skin SPORE as a 
Developmental Research Project (DRP). 
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